Seamus Hussey © ECCO
|
2023 has been another outstanding year of emerging Inflammatory Bowel Disease (IBD) treatments – in adults. Children and young adults remain underserved by clinical trials of IBD therapies. While this age demographic garners much sympathy, and accounts for one-quarter of all new diagnoses, children and young adults are disenfranchised from accessing cutting-edge drug trials by virtue of age alone. Paediatric patients are the almost perfect participants – having generally fewer comorbidities, shorter disease duration and seemingly better treatment responses than adults. The additional challenges posed by trials in this age group have, however, left a relatively barren landscape of industry-sponsored trials in their wake. What, then, are the ongoing challenges, and what have industry and our drug trial community done to level the therapeutic playing field?